Revisiting DNA damage repair, p53-mediated apoptosis and cisplatin sensitivity in germ cell tumors

International Journal of Developmental Biology

Volumn 57, Issue 2-4, 2013, Pages 273-280

  Cavallo, Francesca ^a,b   Feldman, Darren R ^b   Barchi, Marco ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

ERCC1; Homologous recombination (HR); MDM2; Nutlin 3; P53; XPF

Indexed keywords

AZD 2281.; BLEOMYCIN; CISPLATIN; ETOPOSIDE; OLAPARIB; PROTEIN P53; RETINOIC ACID; UNCLASSIFIED DRUG; VINBLASTINE;

APOPTOSIS; ARTICLE; CANCER INCIDENCE; CAUCASIAN; DNA DAMAGE; DNA REPAIR; DRUG RESPONSE; DRUG SENSITIVITY; GERM CELL TUMOR; HUMAN; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; SEMINOMA; TESTIS NONSEMINOMA CANCER; TESTIS TUMOR; TUMOR RECURRENCE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CISPLATIN; DNA DAMAGE; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; TESTICULAR NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84880048400     PISSN: 02146282     EISSN: None     Source Type: Journal    
DOI: 10.1387/ijdb.130135mb     Document Type: Article

References (75)

1. (1997). International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 15: 594-603.
2. Stat bite: Average years of life lost per person dying of cancer. J Natl Cancer Inst 91: 1275.
3. AL-MINAWI, A.Z., LEE, Y.F., HAKANSSON, D., JOHANSSON, F., LUNDIN, C., SALEH-GOHARI, N., SCHULTZ, N., JENSSEN, D., BRYANT, H.E., MEUTH, M. et al., (2009). The ERCC1/XPF endonuclease is required for completion of homologous recombination at DNA replication forks stalled by inter-strand cross-links. Nucleic Acids Res 37: 6400-6413.
4. ANDERSON, P.D., LAM, M.Y., POIRIER, C., BISHOP, C.E. and NADEAU, J.H. (2009). The role of the mouse y chromosome on susceptibility to testicular germ cell tumors. Cancer Res 69: 3614-3618.
5. ANDREWS, P.W. (1984). Retinoic acid induces neuronal differentiation of a cloned human embryonal carcinoma cell line in vitro. Dev Biol 103: 285-293.
6. BARTKOVA, J., RAJPERT-DE MEYTS, E., SKAKKEBAEK, N.E., LUKAS, J. and BARTEK, J. (2007). DNA damage response in human testes and testicular germ cell tumours: biology and implications for therapy. Int J Androl 30: 282-291; discussion 291.
7. BAUER, S., MUHLENBERG, T., LEAHY, M., HOICZYK, M., GAULER, T., SCHULER, M. and LOOIJENGA, L. (2009). Therapeutic potential of Mdm2 inhibition in ma-lignant germ cell tumours. Eur Urol 57: 679-687.
8. BEDFORD, P., FICHTINGER-SCHEPMAN, A.M., SHELLARD, S.A., WALKER, M.C., MASTERS, J.R. and HILL, B.T. (1988). Differential repair of platinum-DNA adducts in human bladder and testicular tumor continuous cell lines. Cancer Res 48: 3019-24.
9. BOSL, G.J. and MOTZER, R.J. (1997). Testicular germ-cell cancer. N Engl J Med 337: 242-253.
10. CAVALLO, F., GRAZIANI, G., ANTINOZZI, A., FELDMAN, F., HOULDSWORTH, J., BOSL, G., CHAGANTI, R., MOYNAHAN, M., JASIN, M. and BARCHI, M. (2012). Reduced proficiency in homologous recombination underlies the high sensitivity of Embryonal Carcinoma Testicular Germ Cell Tumors to cisplatin and poly (ADP-ribose)polymerase inhibition. PLoS One 7: e51563.
11. CHEHAB, N.H., MALIKZAY, A., STAVRIDI, E.S. and HALAZONETIS, T.D. (1999). Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. Proc Natl Acad Sci USA 96: 13777-13782.
12. DATTA, M.W., MACRI, E., SIGNORETTI, S., RENSHAW, A.A. and LODA, M. (2001). Transition from in situ to invasive testicular germ cell neoplasia is associated with the loss of p21 and gain of mdm-2 expression. Mod Pathol 14: 437-442.
13. EINHORN, L.H. and DONOHUE, J. (1977a). Cis-diamminedichloroplatinum, vinblas-tine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 87: 293-298.
14. EINHORN, L.H. and DONOHUE, J.P. (1977b). Chemotherapy for disseminated testicular cancer. Urol Clin North Am 4: 407-426.
15. EINHORN, L.H. and DONOHUE, J.P. (1977c). Improved chemotherapy in dissemi-nated testicular cancer. J Urol 117: 65-69.
16. FOSSA, S.D., CHEN, J., SCHONFELD, S.J., MCGLYNN, K.A., MCMASTER, M.L., GAIL, M.H. and TRAVIS, L.B. (2005). Risk of contralateral testicular cancer: a population-based study of 29, 515 U.S. men. J Natl Cancer Inst 97: 1056-1066.
17. GREENBLATT, M.S., BENNETT, W.P., HOLLSTEIN, M. and HARRIS, C.C. (1994). Mutations in the p53 tumor suppressor gene: clues to cancer etiology and mo-lecular pathogenesis. Cancer Res 54: 4855-4878.
18. GREENE, M.H., KRATZ, C.P., MAI, P.L., MUELLER, C., PETERS, J.A., BRATSLAVSKY, G., LING, A., CHOYKE, P.M., PREMKUMAR, A., BRACCI, J. et al., (2010). Familial testicular germ cell tumors in adults: 2010 summary of genetic risk factors and clinical phenotype. Endocr Relat Cancer 17: R109-R121.
19. GUTEKUNST, M., OREN, M., WEILBACHER, A., DENGLER, M.A., MARKWARDT, C., THOMALE, J., AULITZKY, W.E. and VAN DER KUIP, H. (2011). p53 hypersen-sitivity is the predominant mechanism of the unique responsiveness of testicular germ cell tumor (TGCT) cells to cisplatin. PLoS One 6: e19198.
20. HANADA, K., BUDZOWSKA, M., MODESTI, M., MAAS, A., WYMAN, C., ESSERS, J. and KANAAR, R. (2006). The structure-specific endonuclease Mus81-Eme1 promotes conversion of interstrand DNA crosslinks into double-strands breaks. EMBO J 25: 4921-4932.
21. HANLON NEWELL, A.E., HEMPHILL, A., AKKARI, Y.M., HEJNA, J., MOSES, R.E. and OLSON, S.B. (2008). Loss of homologous recombination or non-homologous end-joining leads to radial formation following DNA interstrand crosslink damage. Cytogenet Genome Res 121: 174-180.
22. HARTMANN, J.T., FOSSA, S.D., NICHOLS, C.R., DROZ, J.P., HORWICH, A., GERL, A., BEYER, J., PONT, J., FIZAZI, K., HECKER, H. et al., (2001). Incidence of metachronous testicular cancer in patients with extragonadal germ cell tumors. J Natl Cancer Inst 93: 1733-1738.
23. HEGAN, D.C., LU, Y., STACHELEK, G.C., CROSBY, M.E., BINDRA, R.S. and GLAZER, P.M. (2010). Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130. Proc Natl Acad Sci USA 107: 2201-2206.
24. IWATO, M., TACHIBANA, O., TOHMA, Y., ARAKAWA, Y., NITTA, H., HASEGAWA, M., YAMASHITA, J. and HAYASHI, Y. (2000). Alterations of the INK4a/ARF locus in human intracranial germ cell tumors. Cancer Res 60: 2113-2115.
25. KANETSKY, P.A., MITRA, N., VARDHANABHUTI, S., LI, M., VAUGHN, D.J., LE-TRERO, R., CIOSEK, S.L., DOODY, D.R., SMITH, L.M., WEAVER, J. et al., (2009). Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer. Nat Genet 41: 811-815.
26. KANTO, S., HIRAMATSU, M., SUZUKI, K., ISHIDOYA, S., SAITO, H., YAMADA, S., SATOH, M., SAITO, S., FUKUZAKI, A. and ARAI, Y. (2004). Risk factors in past histories and familial episodes related to development of testicular germ cell tumor. Int J Urol 11: 640-646.
27. KATAYAMA, K., UENO, M., YAMAUCHI, H., NAKAYAMA, H. and DOI, K. (2002). Ethylnitrosourea-induced apoptosis in primordial germ cells of the rat fetus. Exp Toxicol Pathol 54: 193-196.
28. KERSEMAEKERS, A.M., MAYER, F., MOLIER, M., VAN WEEREN, P.C., OOSTER-HUIS, J.W., BOKEMEYER, C. and LOOIJENGA, L.H. (2002). Role of P53 and MDM2 in treatment response of human germ cell tumors. J Clin Oncol 20: 1551-1561.
29. KNIPSCHEER, P., RASCHLE, M., SMOGORZEWSKA, A., ENOIU, M., HO, T.V., SCHARER, O.D., ELLEDGE, S.J. and WALTER, J.C. (2009). The Fanconi ane-mia pathway promotes replication-dependent DNA interstrand cross-link repair. Science 326: 1698-1701.
30. KOBERLE, B., GRIMALDI, K.A., SUNTERS, A., HARTLEY, J.A., KELLAND, L.R. and MASTERS, J.R. (1997). DNA repair capacity and cisplatin sensitivity of human testis tumour cells. Int J Cancer 70: 551-555.
31. KOBERLE, B., MASTERS, J.R., HARTLEY, J.A. and WOOD, R.D. (1999). Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr Biol 9: 273-276.
32. KOBERLE, B., PAYNE, J., GRIMALDI, K.A., HARTLEY, J.A. and MASTERS, J.R. (1996). DNA repair in cisplatin-sensitive and resistant human cell lines measured in specific genes by quantitative polymerase chain reaction. Biochem Pharmacol 52: 1729-1734.
33. KOBERLE, B., ROGINSKAYA, V., ZIMA, K.S., MASTERS, J.R. and WOOD, R.D. (2008). Elevation of XPA protein level in testis tumor cells without increasing resistance to cisplatin or UV radiation. Mol Carcinog 47: 580-586.
34. KORKOLA, J.E., HOULDSWORTH, J., BOSL, G.J. and CHAGANTI, R.S. (2009a). Molecular events in germ cell tumours: linking chromosome-12 gain, acquisition of pluripotency and response to cisplatin. BJU Int 104: 1334-1338.
35. KORKOLA, J.E., HOULDSWORTH, J., FELDMAN, D.R., OLSHEN, A.B., QIN, L.X., PATIL, S., REUTER, V.E., BOSL, G.J. and CHAGANTI, R.S. (2009b). Identification and validation of a gene expression signature that predicts outcome in adult men with germ cell tumors. J Clin Oncol 27: 5240-5247.
36. KOSTER, R., TIMMER-BOSSCHA, H., BISCHOFF, R., GIETEMA, J.A. and DE JONG, S. (2011). Disruption of the MDM2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway. Cell Death Dis 2: e148.
37. LEVINE, A.J. (1997). p53, the cellular gatekeeper for growth and division. Cell 88: 323-331.
38. LI, B., CHENG, Q., LI, Z. and CHEN, J. (2010). p53 inactivation by MDM2 and MDMX negative feedback loops in testicular germ cell tumors. Cell Cycle 9: 1411-1420.
39. LI, X. and HEYER, W.D. (2008). Homologous recombination in DNA repair and DNA damage tolerance. Cell Res 18: 99-113.
40. LILFORD, R., JONES, A.M., BISHOP, D.T., THORNTON, J. and MUELLER, R. (1994). Case-control study of whether subfertility in men is familial. BMJ 309: 570-573.
41. LOOIJENGA, L.H., GILLIS, A.J., STOOP, H., BIERMANN, K. and OOSTERHUIS, J.W. (2011). Dissecting the molecular pathways of (testicular) germ cell tumour pathogenesis; from initiation to treatment-resistance. Int J Androl 34: e234-e251.
42. LUTZKER, S.G. (1998). P53 tumour suppressor gene and germ cell neoplasia. APMIS 106: 85-89.
43. MASTERS, J.R., THOMAS, R., HALL, A.G., HOGARTH, L., MATHESON, E.C., CATTAN, A.R. and LOHRER, H. (1996). Sensitivity of testis tumour cells to chemotherapeutic drugs: role of detoxifying pathways. Eur J Cancer 32A: 1248-1253.
44. MCGLYNN, K.A. and COOK, M.B. (2009). Etiologic factors in testicular germ-cell tumors. Future Oncol 5: 1389-1402.
45. MCGLYNN, K.A., QURAISHI, S.M., GRAUBARD, B.I., WEBER, J.P., RUBERTONE, M.V. and ERICKSON, R.L. (2008). Persistent organochlorine pesticides and risk of testicular germ cell tumors. J Natl Cancer Inst 100: 663-671.
46. MCGURK, C.J., CUMMINGS, M., KOBERLE, B., HARTLEY, J.A., OLIVER, R.T. and MASTERS, J.R. (2006). Regulation of DNA repair gene expression in human cancer cell lines. J Cell Biochem 97: 1121-1136.
47. MEIJER, C., TIMMER, A., DE VRIES, E.G., GROTEN, J.P., KNOL, A., ZWART, N., DAM, W.A., SLEIJFER, D.T. and MULDER, N.H. (2000). Role of metallothionein in cisplatin sensitivity of germ-cell tumours. Int J Cancer 85: 777-781.
48. MOLDOVAN, G.L. and D'ANDREA, A.D. (2009). FANCD2 hurdles the DNA interstrand crosslink. Cell 139: 1222-1224.
49. MOLLER, H. and SKAKKEBAEK, N.E. (1997). Testicular cancer and cryptorchidism in relation to prenatal factors: case-control studies in Denmark. Cancer Causes Control 8: 904-912.
50. MOYNAHAN, M.E., CHIU, J.W., KOLLER, B.H. and JASIN, M. (1999). Brca1 controls homology-directed DNA repair. Mol Cell 4: 511-518.
51. MOYNAHAN, M.E., CUI, T.Y. and JASIN, M. (2001a). Homology-directed dna repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res 61: 4842-4850.
52. MOYNAHAN, M.E., PIERCE, A.J. and JASIN, M. (2001b). BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell 7: 263-272.
53. NAKANISHI, K., CAVALLO, F., PERROUAULT, L., GIOVANNANGELI, C., MOYNA-HAN, M.E., BARCHI, M., BRUNET, E. and JASIN, M. (2011). Homology-directed Fanconi anemia pathway cross-link repair is dependent on DNA replication. Nat Struct Mol Biol 18: 500-503.
54. NAKANISHI, K., YANG, Y.G., PIERCE, A.J., TANIGUCHI, T., DIGWEED, M., D'ANDREA, A.D., WANG, Z.Q. and JASIN, M. (2005). Human Fanconi anemia monoubiquitination pathway promotes homologous DNA repair. Proc Natl Acad Sci USA 102: 1110-1115.
55. NIEDERNHOFER, L.J., ODIJK, H., BUDZOWSKA, M., VAN DRUNEN, E., MAAS, A., THEIL, A.F., DE WIT, J., JASPERS, N.G., BEVERLOO, H.B., HOEIJMAKERS, J.H. et al., (2004). The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks. Mol Cell Biol 24: 5776-5787.
56. PENG, H.Q., HOGG, D., MALKIN, D., BAILEY, D., GALLIE, B.L., BULBUL, M., JEW-ETT, M., BUCHANAN, J. and GOSS, P.E. (1993). Mutations of the p53 gene do not occur in testis cancer. Cancer Res 53: 3574-3578.
57. PIERCE, A.J., JOHNSON, R.D., THOMPSON, L.H. and JASIN, M. (1999). XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev 13: 2633-2638.
58. PRENER, A., ENGHOLM, G. and JENSEN, O.M. (1996). Genital anomalies and risk for testicular cancer in Danish men. Epidemiology 7: 14-19.
59. PRIVES, C. and HALL, P.A. (1999). The p53 pathway. J Pathol 187: 112-126.
60. ROSENBERG, C., VAN GURP, R.J., GEELEN, E., OOSTERHUIS, J.W. and LOOI-JENGA, L.H. (2000). Overrepresentation of the short arm of chromosome 12 is related to invasive growth of human testicular seminomas and nonseminomas. Oncogene 19: 5858-5862.
61. SARK, M.W., TIMMER-BOSSCHA, H., MEIJER, C., UGES, D.R., SLUITER, W.J., PETERS, W.H., MULDER, N.H. and DE VRIES, E.G. (1995). Cellular basis for differential sensitivity to cisplatin in human germ cell tumour and colon carcinoma cell lines. Br J Cancer 71: 684-690.
62. SHIEH, S.Y., IKEDA, M., TAYA, Y. and PRIVES, C. (1997). DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91: 325-334.
63. SKAKKEBAEK, N.E. (1972). Possible carcinoma-in-situ of the testis. Lancet 2: 516-517.
64. TAKATA, M., SASAKI, M.S., TACHIIRI, S., FUKUSHIMA, T., SONODA, E., SCHILD, D., THOMPSON, L.H. and TAKEDA, S. (2001). Chromosome instability and defective recombinational repair in knockout mutants of the five Rad51 paralogs. Mol Cell Biol 21: 2858-2866.
65. THACKER, J. (2005). The RAD51 gene family, genetic instability and cancer. Cancer Lett 219: 125-135.
66. THOMPSON, T., TOVAR, C., YANG, H., CARVAJAL, D., VU, B.T., XU, Q., WAHL, G.M., HEIMBROOK, D.C. and VASSILEV, L.T. (2004). Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. J Biol Chem 279: 53015-53022.
67. TIMMER-BOSSCHA, H., DE VRIES, E.G., MEIJER, C., OOSTERHUIS, J.W. and MULDER, N.H. (1998). Differential effects of all-trans-retinoic acid, docosahexaenoic acid, and hexadecylphosphocholine on cisplatin-induced cytotoxicity and apoptosis in a cisplantin-sensitive and resistant human embryonal carcinoma cell line. Cancer Chemother Pharmacol 41: 469-476.
68. USANOVA, S., PIEE-STAFFA, A., SIED, U., THOMALE, J., SCHNEIDER, A., KAINA, B. and KOBERLE, B. (2010). Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression. Mol Cancer 9: 248.
69. VALENTINE, J.M., KUMAR, S. and MOUMEN, A. (2011). A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation. BMC Cancer 11: 79.
70. VERMA, R., RIGATTI, M.J., BELINSKY, G.S., GODMAN, C.A. and GIARDINA, C. (2010). DNA damage response to the Mdm2 inhibitor nutlin-3. Biochem Pharmacol 79: 565-574.
71. VOORHOEVE, P.M., LE SAGE, C., SCHRIER, M., GILLIS, A.J., STOOP, H., NAGEL, R., LIU, Y.P., VAN DUIJSE, J., DROST, J., GRIEKSPOOR, A. et al., (2006). A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell 124: 1169-1181.
72. WANG, L.C. and GAUTIER, J. (2010). The Fanconi anemia pathway and ICL repair: implications for cancer therapy. Crit Rev Biochem Mol Biol 45: 424-439.
73. WANG, W. and HU, Y. (2012). Small molecule agents targeting the p53-MDM2 pathway for cancer therapy. Med Res Rev 32: 1159-1196.
74. WELSH, C., DAY, R., MCGURK, C., MASTERS, J.R., WOOD, R.D. and KOBERLE, B. (2004). Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines. Int J Cancer 110: 352-3561.
75. WYLIE, C. (1999). Germ cells. Cell 96: 165-174.